Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study

被引：0
|
作者：
Christiane Querfeld
Winnie W. Nelson
Deval Gor
Chris L. Pashos
Quan V. Doan
Marco Turini
James T. Angello
Larisa J. Geskin
机构：
[1] City of Hope and Beckman Research Institute,Department of Dermatology
[2] Helsinn Therapeutics (U.S.),undefined
[3] Inc.,undefined
[4] Genesis Research,undefined
[5] LLC.,undefined
[6] Helsinn Healthcare SA,undefined
[7] Columbia University,undefined
来源：
Dermatology and Therapy | 2022年 / 12卷
关键词：
Chlormethine gel; Mechlorethamine gel; Mycosis fungoides-type cutaneous T-cell lymphoma; MF-CTCL; Registry; Real-world setting; Treatment patterns;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2781 / 2795
页数：14
相关论文
共 30 条
  • [21] The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma (vol 22, pg 407, 2021)
    Kim, Ellen J.
    Guitart, Joan
    Querfeld, Christiane
    Girardi, Michael
    Musiek, Amy
    Akilov, Oleg E.
    Angello, James T.
    Bailey, William L.
    Geskin, Larisa J.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (03) : 425 - 425
  • [22] Chlormethine Gel for Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: A Review of Efficacy and Safety in Clinical Trial and Real-World Settings (vol 39, pg 3979,2022)
    Wehkamp, Ulrike
    Ardigo, Marco
    Papadavid, Evangelia
    Querfeld, Christiane
    Nikbakht, Neda
    ADVANCES IN THERAPY, 2023, 40 (03) : 1299 - 1300
  • [23] Real-world evidence study of brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma
    Mitteldorf, C.
    de Masson, A.
    Beylot-Barry, M.
    Wobster, M.
    Zomas, A.
    Stache, V.
    Assaf, C.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S77 - S78
  • [24] Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sezary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data
    Remak, Edit
    Hawkins, Neil
    Jones, Trefor
    Otley, Marissa
    Twigger, Robert
    Prince, Miles
    EUROPEAN JOURNAL OF CANCER, 2021, 156 : S18 - S18
  • [25] PATIENTS' EXPERIENCES WITH MYCOSIS FUNGOIDES/SEZARY SYNDROME - CUTANEOUS T-CELL LYMPHOMA (MF/SS-CTCL): EVIDENCE FROM QUALITATIVE RESEARCH OF A PATIENT REPORTED OUTCOME (PRO) MEASURE DEVELOPED ON AN ONLINE RESEARCH PLATFORM
    Towner, A.
    Raja, P.
    Braverman, J.
    Harrington, M.
    Simacek, K.
    Nagao, M.
    Sepassi, M.
    VALUE IN HEALTH, 2015, 18 (03) : A25 - A25
  • [26] COMBINED RESULTS FROM THE PHASE 3 MAVORIC STUDY: PRIMARY SAFETY AND EFFICACY, WITH POST HOC ANALYSES ON EFFICACY BY PRIOR SYSTEMIC THERAPY, LONG TERM EXPOSURE OF MOGAMULIZUMAB (MOGA) IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL), AND EFFICACY, AND SAFETY IN EARLY STAGE MYCOSIS FUNGOIDES (MF) PATIENTS
    Zinzani, P. L.
    Kim, Y.
    Bagot, M.
    Scarisbrick, J.
    Geskin, L.
    Ortiz-Romero, P.
    HAEMATOLOGICA, 2019, 104 : 46 - 46
  • [27] Activity and safety of Bexarotene as maintenance therapy in CTCL patients (Mycosis Fungoides stage IIB-IV, Sezary Syndrome, peripheral T-cell lymphoma) with stable disease or remission after systemic treatments: A prospective multicenter trauil from the Italian Group of Cutaneous Lymphoma (GILC)
    Quaglino, P.
    Pimpinelli, N.
    Alaibac, M.
    Quintini, G.
    Bernengo, M. G.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 : 6 - 7
  • [28] Real-World Treatment Patterns and Clinical Outcomes with Brentuximab Vedotin or Other Standard Therapies in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Chart Review Study in the United States
    Barta, Stefan K.
    Liu, Nicholas
    DerSarkissian, Maral
    Chang, Rose
    Ye, Mingchen
    Duh, Mei Sheng
    Surinach, Andy
    Fanale, Michelle A.
    Yu, Kristina S.
    BLOOD, 2022, 140 : 5167 - 5169
  • [29] Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study
    Scarisbrick, Julia
    Horwitz, Steven M.
    Prince, H. Miles
    Whittaker, Sean
    Duvic, Madeleine
    Kim, Youn H.
    Quaglino, Pietro
    Zinzani, Pier Luigi
    Bechter, Oliver
    Eradat, Herbert
    Pinter-Brown, Lauren
    Akilov, Oleg
    Geskin, Larisa
    Sanches, Jose
    Ortiz-Romero, Pablo
    Lisano, Julie
    Brown, Lisa
    Bunn, Veronica
    Little, Meredith
    Dummer, Reinhard
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : S31 - S31
  • [30] Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study
    Shouse, Geoffrey
    Kaempf, Andy
    Gordon, Max J.
    Yashar, David
    Sigmund, Audrey M.
    Smilnak, Gordon
    Bair, Steven M.
    Mian, Agrima
    Fitzgerald, Lindsey A.
    Bajwa, Amneet
    Jaglowski, Samantha
    Bailey, Neil
    Shadman, Mazyar
    Patel, Krish
    Stephens, Deborah M.
    Kamdar, Manali
    Hill, Brian T.
    Gauthier, Jordan
    Karmali, Reem
    Nastoupil, Loretta J.
    Kittai, Adam S.
    Danilov, Alexey, V
    BLOOD, 2022, 140 : 2048 - 2050
123